Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
about
Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidenceHelicobacter pylori and gastric acid: an intimate and reciprocal relationshipTreatment of Helicobacter pylori infection 2016.Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection.The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.Helicobacter pylori therapy: a paradigm shift.Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori.Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies.Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese MenComparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.Cost-Effectiveness Analysis of Helicobacter pylori Diagnostic Methods in Patients with Atrophic Gastritis.A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled TrialEvaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data.Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).Ilaprazole for the treatment of gastro-esophageal reflux.Population screening and treatment of Helicobacter pylori infection.Vonoprazan fumarate for the management of acid-related diseases.Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.Treatment of Helicobacter pylori infection 2017.The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey).Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients.Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin.Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?Immune thrombocytopenia induced by vonoprazan fumarate: a single center retrospective study.Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan.Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori.Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
P2860
Q28072552-C3867C50-1F5E-4FF4-8372-E7BBD5FDDD72Q28077416-29D9D5F2-8A18-4E89-A864-5465DC47DA02Q30248450-D88CE43F-7C08-478E-B4B4-BC9F29C2CFB1Q33639114-FCD04489-E5B3-44DA-913A-B6B91DDA3903Q33751142-140CA769-0EC3-4619-A137-2A5088EBB54DQ33874650-CD291C48-31DB-4463-87DA-C54C1C76FE23Q36369941-00B73EB5-0B6F-4408-8051-4DCF2AC4C7C4Q37082187-23A8B083-A191-4376-BFA2-A8D1D123252CQ37393730-93631B3B-4062-4CF9-A963-C81675BA7F66Q37533456-17A123EF-28EE-4F18-8AC5-03737C3C7AFDQ37553533-44838D7C-DE63-444C-BCF1-EF651F6637ACQ37625226-DB1FCCDD-5A1A-4934-BDF2-DBF88EB98926Q37694256-F2BD2697-6237-452B-A8E0-27ACA85757F9Q37697753-5011E4B6-FD7D-4588-B0F9-CD2DD73D7AA1Q37699963-6D60C31D-EF0B-464D-80E1-A5843F769849Q38381807-80997AA7-B915-4135-ADBF-5EE7F354C304Q38621376-69BA00B4-8510-40D1-AD85-F87593AF5D00Q38649076-70AF11FF-5BF7-4722-B2BE-908A16BCB69CQ38861693-1901D3E8-5A96-455A-A030-8779ED088F9FQ38947217-F237FC55-6F81-40C6-B44E-BD3D70D70C0FQ39067619-9CFB044F-A290-437E-97CC-1FEE26701ACCQ39402205-54AF6125-A2E2-46AD-A9FA-A25393E034CBQ39406352-2212C737-B4E0-4C68-8DFE-2E89BDC9407FQ40054316-A45A087A-DC73-44B1-9AF2-7BE0FB8569CEQ40153376-7137A874-FFD8-4920-B943-9B3C9A28A98CQ40314735-C432818D-5F3A-4ADF-93F3-94F5B6463FFCQ40468767-B60E3D3D-C6C8-4C0C-B6F9-7E5B8DACBA40Q40502852-318B28C6-3A51-4D1F-92FA-EE67981CB8FBQ40555482-1470A22D-2652-49DE-92DE-07FC593A7ABDQ40572311-E496D768-65AD-4DB6-AD03-F7C4CB97F768Q40608496-0E094F20-7998-4873-8067-6C507A959851Q47158212-6D5BD893-69E8-4C11-9771-06F3A69738AAQ47225018-97D16EF3-7D45-414F-B4C6-87B0D94464A6Q47672283-85615D58-7FF6-4A41-B98B-977C2F9C6BB8Q47995761-7126A868-83E6-4DA6-AD2D-9DD0767CB1CDQ48104849-A79B361C-A1D2-44C7-8B50-F52BA65791C0Q48106665-EE0D617F-C2C4-47A2-8F86-BAF6A2BE2D7DQ48168548-2C25A6E2-0292-4C6E-95DD-45A76D8E22B1Q48291731-3C0831C0-52EB-4F6F-A401-31AC756013ECQ48339888-70F1A5F4-9D48-42E4-ACBE-42B061051ACE
P2860
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vonoprazan, a novel potassium- ...... randomised, double-blind study
@en
Vonoprazan, a novel potassium- ...... andomised, double-blind study.
@nl
type
label
Vonoprazan, a novel potassium- ...... randomised, double-blind study
@en
Vonoprazan, a novel potassium- ...... andomised, double-blind study.
@nl
prefLabel
Vonoprazan, a novel potassium- ...... randomised, double-blind study
@en
Vonoprazan, a novel potassium- ...... andomised, double-blind study.
@nl
P2093
P2860
P1433
P1476
Vonoprazan, a novel potassium- ...... randomised, double-blind study
@en
P2093
Akira Nishimura
Kazunari Murakami
Madoka Shiino
Masahiro Asaka
Nobuo Funao
Yuuichi Sakurai
P2860
P304
P356
10.1136/GUTJNL-2015-311304
P407
P577
2016-03-02T00:00:00Z